Lung cancer (LC) is the leading cause of cancer-related deaths. Oxidative DNA damage may contribute to the cancer risk. The antioxidant paraoxonase (PON1) is an endogenous free radical scavenger in the human body. The aim of this study was to determine serum PON1 and arylesterase (ARE) activities in patients with newly diagnosed LC.
1 January 2007 in Methods and Findings in Experimental and Clinical Pharmacology
Cyclophosphamide (CPA) and adriamycin (ADR) are widely used drugs for cancer chemotherapy. It has been reported that CPA and ADR singly or in combination could alter activities of a variety of drug-metabolizing enzymes in animals via multiple mechanisms. However, the effects of CPA/ADR on drug metabolism are largely unknown in human beings. Losartan metabolism has been suggested as a marker for determination of CYP2C9 activity. Caffeine is a commonly used probe to assess the metabolic activities of CYP1A2, CYP2A6, N-acetyltransferase 2 (NAT2) and xanthine oxidase (XO). The present study was designed to analyze the effects of CPA/ADR on these drug-metabolizing enzymes by using losartan and caffeine as probe drugs. A single oral dose of 25 mg losartan and a cup of instant coffee was given to 15 breast cancer patients on three occasions (before, and 2-4 h and 3 weeks after the adjuvant CPA/ADR chemotherapy [600 mg CPA/m2/day, 60 mg ADR/m2/day]). Losartan, caffeine and their metabolites were analyzed by using high-pressure liquid chromatography. When compared with baseline, CYP1A2 activity was increased by 20% and CYP2C9 activity was decreased by 315% 3 weeks after the administration of CPA/ADR chemotherapy (p = 0.05). The chemotherapy did not change the activities of CYP2A6, NAT2 or XO. CPA/ADR treatment caused a differential effect on drug-metabolizing enzyme activities, and this may contribute to predicting the efficacy and toxicity of chemotherapeutics, as well as understanding the drug-drug interactions.
Amaç: Bu araştırma kanserli hastalarda hastalık algısını ve yaşam kalitesini incelemek amacıyla tanımlayıcı olarak yapılmıştır.Materyal ve metod: Araştırmanın örneklemini Aralık 2019-Şubat 2020 tarihleri arasında bir eğitim araştırma hastanesinin onkoloji kliniğinde yatarak ve ayaktan tedavi gören 151 kanserli hasta oluşturmuştur. Veriler Kişisel Tanıtım Formu, Hastalık Algısı Ölçeği (HAÖ), Yaşam Kalitesi İndeksi –Kanser Versiyonu-III (QOL-CV) kullanılarak toplanmıştır. Veriler SPSS 25 programında tanımlayıcı istatistikler, Independent Samples t, Kruskal Wallis ve Mann- Whitney U ile değerlendirilmiştir.Bulgular: Hastaların % 58.3’ ünün kadın, %29.1’inin kolon kanseri olduğu ve %11.9’unun hastalık hakkında bilgi sahibi olmadığı bulunmuştur. HAÖ alt ölçeklerinden hastaların kişisel kontrol algısı puan ortalamasının (23.00 ± 3.35), QOL-CV alt ölçeklerinden ise aile alt ölçeği puan ortalamasının en yüksek (26.97±5.04) olduğu bulunmuştur. Toplam QOL-CV puan ortalaması ise 23.44±4.42 olarak saptanmıştır. Sonuç: Hastaların kişisel kontrol algısı ve yaşam kalitesi aile alt boyutu en yüksek, toplam yaşam kalitesi ise orta düzeydedir.
1 January 2021 in Cancer Treatment and Research Communications
Sunitinib malate is a multitargeted oral tyrosine kinase inhibitor (TKI) which is used in treatment of metastatic renal cell carcinoma with side effects such as diarrhea, mucositis, asthenia and myelosuppression. Serious toxicity associated with sunitinib is a rare situation. However; there are few cases reported in the literature. As a result of the inhibition that is caused by sunitinib malate agent at the receptor level, vascular endothelial growth factor (VEGF) level increases. These increased VEGF levels are considered to having a positive contribution on neurological side effects. Neurotoxicity that is related with the usage of sunitinib malate for two weeks will be presented in this case report.